CAR-T cell therapy for autoimmune diseases: current clinical trial landscape and the next wave of development

Qingyu Chen, Yuxin Zhu, Qianqi Xu, Yemeng He, Yaoyi Wang, Ziyue Wang, Weisong Dong · 2026

Read CAR-T cell therapy for autoimmune diseases: current clinical trial landscape and the next wave of development by Qingyu Chen, Yuxin Zhu, Qianqi Xu, Yemeng He, Yaoyi Wang, Ziyue Wang, Weisong Dong (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13260344.txt.

Description

Qingyu Chen and colleagues surveyed in 2026 the clinical trial landscape for CAR-T cell therapy in autoimmune disease and sketched what should come next. CAR-T therapy engineers a patient's own immune cells to hunt a chosen target, a method first proven in blood cancers. Early use against lupus, muscle inflammation, and systemic sclerosis has produced deep remissions in hard-to-treat cases.

A snapshot of trial listings from April 2026 shows fast growth but narrow focus. Most programs aim at the CD19 target and sit in early phases, clustered in few countries and diseases. The authors argue the next wave needs finer biology rather than more trials alone. They point to plasma cell targets, dual-target designs, off-the-shelf products, and cells built inside the body. Durability, relapse, and cost remain open questions.

Catalog record

CREATORQingyu Chen, Yuxin Zhu, Qianqi Xu, Yemeng He, Yaoyi Wang, Ziyue Wang, Weisong Dong
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13260344

Browse the full library · About the Tower of Babel